| Autor: |
Wu J; Department of Vascular Surgery, Quzhou People's Hospital, Quzhou City, 324000, Zhejiang Province, China., Liao S; Department of Vascular Surgery, Quzhou People's Hospital, Quzhou City, 324000, Zhejiang Province, China., Hu Q; Department of Vascular Surgery, Quzhou People's Hospital, Quzhou City, 324000, Zhejiang Province, China., Wu S; Department of Vascular Surgery, Quzhou People's Hospital, Quzhou City, 324000, Zhejiang Province, China., Qiu S; Department of Cardio-Thoracic Surgery, Quzhou People's Hospital, Quzhou City, 324000, Zhejiang Province, China., Cheng G; Department of Vascular Surgery, Quzhou People's Hospital, Quzhou City, 324000, Zhejiang Province, China., Li X; Department of Vascular Surgery, Quzhou People's Hospital, Quzhou City, 324000, Zhejiang Province, China., Lu W; Department of Vascular Surgery, Quzhou People's Hospital, Quzhou City, 324000, Zhejiang Province, China. |
| Abstrakt: |
This article prepared a simvastatin-NLCs for the treatment of arteriosclerotic occlusive disease of lower limbs. Taking the size distribution, polydispersity coefficient, encapsulation efficiency and drug loading of simvastatin-NLCs as evaluation indicators, various prescription factors of simvastatin- NLCs were investigated. The in vitro release behavior and stability of simvastatin-NLCs were also investigated. A hyperlipidemia rat model was established using high-fat diets. SD rats fed ordinary diet were set as normal control groups. 20 rats, 20 in the simvastatin group and 20 in the simvastatin nanocarrier group. After 5 weeks of drug intervention, the rats were sacrificed and the aorta was taken to determine the smooth muscle cell apoptosis rate. Studies have shown that simvastatin nanocarriers can more effectively reduce blood lipids in hyperlipidemia rats, increase the rate of smooth muscle cell apoptosis in hyperlipidemia rats, and delay the onset of atherosclerosis. |
